다우존스 지수

실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Lexicon Pharmaceuticals Inc (LXRX)
Lexicon Pharmaceuticals Inc (LXRX) 뉴스

LXRX

Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:LXRX

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/16	13:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/15	06:05	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/14	20:00	GlobeNewswire Inc.	New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/14	05:05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/14	05:04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/14	05:03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/14	05:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/14	05:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/11	06:14	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/11	05:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/09	20:30	GlobeNewswire Inc.	Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/05/03	05:05	GlobeNewswire Inc.	Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/04/29	22:00	GlobeNewswire Inc.	Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/04/29	20:00	GlobeNewswire Inc.	Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/04/18	21:00	GlobeNewswire Inc.	Lexicon Pharmaceuticals to Host 2024 Investor Day	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/04/03	21:00	GlobeNewswire Inc.	Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/25	22:20	GlobeNewswire Inc.	Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/12	21:00	GlobeNewswire Inc.	New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/12	05:25	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/11	20:26	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/11	20:15	GlobeNewswire Inc.	Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/11	20:05	GlobeNewswire Inc.	Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/11	20:00	GlobeNewswire Inc.	Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/01	06:29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/03/01	06:28	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/02/13	06:19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/02/13	06:18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/02/13	06:17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/02/13	06:16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc
2024/02/13	06:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LXRX	Lexicon Pharmaceuticals Inc

검색 관련기사 보기:NASDAQ:LXRX

1 2 3 4 5 6 7 8 9 10 다음 >>

Vontobel Financial Produ...

Eib Tf 1,625% Mz25 Usd

Lattice Semiconductor

Wt Ftse100 1x S

Rl Fin. Bds3 28

Big Rock Brewery

Societe Generale 1.375% ...

Element Finance

대신증권우

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관